Phenotypic screening of a library of compounds against metastatic and non-metastatic clones of a canine mammary gland tumour cell line

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 288-296

  Saeki, K ^a   Watanabe, M ^b   Michishita, M ^c   Tsuboi, M ^a   Sugano, S ^b   Yoshitake, R ^a   Murai, K ^a   Tanaka, Y ^a   Ong, S M ^a   Saito, T ^a   Matsumoto, K ^a   Fujita, N ^a   Nishimura, R ^a   Nakagawa, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Canine; Chemotherapy; Compound screening; Mammary gland tumour cell lines; Metastases; Mitochondrial respiratory chain complex inhibitors

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; BLEOMYCIN; CITRININ; COMPLEMENTARY DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OLIGOMYCIN; REACTIVE OXYGEN METABOLITE; ROTENONE; THAPSIGARGIN; TRANSCRIPTOME; TUNICAMYCIN;

ANIMAL CELL; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CANINE MAMMARY GLAND TUMOR; CLONAL CELL LINE; CONTROLLED STUDY; DNA MICROARRAY; DOG; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; METASTASIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL CLONE; DOG DISEASES; FEMALE; GENE EXPRESSION REGULATION; MAMMARY NEOPLASMS, ANIMAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLONE CELLS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; TRANSCRIPTOME;

EID: 84937526896     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.04.025     Document Type: Article

References (57)

1. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
2. Boichuk S., Lee D.J., Mehalek K.R., Makielski K.R., Wozniak A., Seneviratne D.S., Korzeniewski N., Cuevas R., Parry J.A., Brown M.F., et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Research 2014, 74:1200-1213.
3. Chang S.-C., Chang C.-C., Chang T.-J., Wong M.-L. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). Journal of the American Veterinary Medical Association 2005, 227:1625-1629.
4. Cheng S., Tada M., Hida Y., Asano T., Kuramae T., Takemoto N., Hamada J.-I., Miyamoto M., Hirano S., Kondo S., et al. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. Journal of Surgical Research 2008, 146:104-109.
5. Clemente M., Pérez-Alenza M.D., Peña L. Metastasis of canine inflammatory versus non-inflammatory mammary tumours. Journal of Comparative Pathology 2010, 143:157-163.
6. Coulom H., Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. Journal of Neuroscience 2004, 24:10993-10998.
7. Di Stefano M., Conforti L. Diversification of NAD biological role: The importance of location. FEBS Journal 2013, 280:4711-4728.
8. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., Abel U., Arens A., Weichert W., Brand K., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
9. Dorn C.R., Taylor D.O., Schneider R., Hibbard H.H., Klauber M.R. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 1968, 40:307-318.
10. Drasin D.J., Robin T.P., Ford H.L. Breast cancer epithelial-to-mesenchymal transition: Examining the functional consequences of plasticity. Breast Cancer Research 2011, 13:226.
11. Emami Riedmaier A., Fisel P., Nies A.T., Schaeffeler E., Schwab M. Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects. Trends in Pharmacological Sciences 2013, 34:126-135.
12. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
13. Gama A., Paredes J., Gärtner F., Alves A., Schmitt F. Expression of E-cadherin, P-cadherin and β-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. The Veterinary Journal 2008, 177:45-53.
14. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
15. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 2012, 366:883-892.
16. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
17. Gusterson B.A., Stein T. Human breast development. Seminars in Cell and Developmental Biology 2012, 23:567-573.
18. Han Y.H., Park W.H. Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung Cancer (Amsterdam, Netherlands) 2009, 65:150-160.
19. Han Y.H., Park W.H. Tiron, a ROS scavenger, protects human lung cancer Calu-6 cells against antimycin A-induced cell death. Oncology Reports 2009, 21:253-261.
20. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer 2013, 13:714-726.
21. + treatment prevents rotenone-induced apoptosis and necrosis of differentiated PC12 cells. Neuroscience Letters 2014, 560:46-50.
22. Hothorn T., Bretz F., Westfall P. Simultaneous inference in general parametric models. Biometrical Journal 2008, 50:346-363.
23. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., Hayashi J.-I. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664.
24. Kashiwagi S., Yashiro M., Takashima T., Aomatsu N., Ikeda K., Ogawa Y., Ishikawa T., Hirakawa K. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: Usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Research 2011, 13:R122.
25. Kitambi S.S., Toledo E.M., Usoskin D., Wee S., Harisankar A., Svensson R., Sigmundsson K., Kalderén C., Niklasson M., Kundu S., et al. Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule. Cell 2014, 157:313-328.
26. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., Rein A., Sauter G., Kallioniemi O.-P., Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033.
27. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
28. Liang J., Mills G.B. AMPK: A contextual oncogene or tumor suppressor?. Cancer Research 2013, 73:2929-2935.
29. Liu X., Chhipa R.R., Pooya S., Wortman M., Yachyshin S., Chow L.M.L., Kumar A., Zhou X., Sun Y., Quinn B., et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proceedings of the National Academy of Sciences of the United States America 2014, 111:E435-E444.
30. Lonardo E., Cioffi M., Sancho P., Sanchez-Ripoll Y., Trabulo S.M., Dorado J., Balic A., Hidalgo M., Heeschen C. Metformin targets the metabolic Achilles heel of human pancreatic cancer stem cells. PLoS ONE 2013, 8:e76518.
31. Mamane Y., Petroulakis E., LeBacquer O., Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422.
32. Maryanovich M., Gross A. A ROS rheostat for cell fate regulation. Trends in Cell Biology 2013, 23:129-134.
33. McCormack N., O'Dea S. Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins. Cellular Signalling 2013, 25:2856-2862.
34. Michishita M., Akiyoshi R., Suemizu H., Nakagawa T., Sasaki N., Takemitsu H., Arai T., Takahashi K. Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. The Veterinary Journal 2012, 193:508-513.
35. Murai K., Nakagawa T., Endo Y., Kamida A., Yoshida K., Mochizuki M., Nishimura R., Sasaki N. Establishment of a pair of novel cloned tumour cell lines with or without metastatic potential from canine mammary adenocarcinoma. Research in Veterinary Science 2012, 93:468-472.
36. Oguri T., Achiwa H., Sato S., Bessho Y., Takano Y., Miyazaki M., Muramatsu H., Maeda H., Niimi T., Ueda R. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: A role of ABCC5 in gemcitabine sensitivity. Molecular Cancer Therapeutics 2006, 5:1800-1806.
37. Overall C.M., Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews. Cancer 2006, 6:227-239.
38. Pagliarani A., Nesci S., Ventrella V. Modifiers of the oligomycin sensitivity of the mitochondrial F1F0-ATPase. Mitochondrion 2013, 13:312-319.
39. R Development Core Team R: A Language and Environment for Statistical Computing 2013, R Foundation for Statistical Computing, Vienna, Austria., accessed 29 April 2015. http://www.R-project.org.
40. Remacle A.G., Noël A., Duggan C., McDermott E., O'Higgins N., Foidart J.M., Duffy M.J. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. British Journal of Cancer 1998, 77:926-931.
41. Restucci B., Maiolino P., Martano M., Esposito G., Filippis D.D., Borzacchiello G., Muzio L.L. Expression of β-catenin, E-cadherin and APC in canine mammary tumors. Anticancer Research 2007, 27:3083-3089.
42. Rizos C.V., Elisaf M.S. Metformin and cancer. European Journal of Pharmacology 2013, 705:96-108.
43. Rostami M., Tateyama S., Uchida K., Naitou H., Yamaguchi R., Otsuka H. Tumors in domestic animals examined during a ten-year period (1980 to 1989) at Miyazaki University. Journal of Veterinary Medical Science 1994, 56:403-405.
44. Santos A.A., Lopes C.C., Marques R.M., Amorim I.F., Gärtner M.F., de Matos A.J.F. Matrix metalloproteinase-9 expression in mammary gland tumors in dogs and its relationship with prognostic factors and patient outcome. American Journal of Veterinary Research 2012, 73:689-697.
45. Seipke R.F., Hutchings M.I. The regulation and biosynthesis of antimycins. Beilstein Journal of Organic Chemistry 2013, 9:2556-2563.
46. Shao M.-M., Chan S.K., Yu A.M.C., Lam C.C.F., Tsang J.Y.S., Lui P.C.W., Law B.K.B., Tan P.-H., Tse G.M. Keratin expression in breast cancers. International Journal of Pathology 2012, 461:313-322.
47. Song C.W., Lee H., Dings R.P.M., Williams B., Powers J., Santos T.D., Choi B.-H., Park H.J. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports 2012, 2:362.
48. Sugimachi K., Yokobori T., Iinuma H., Ueda M., Ueo H., Shinden Y., Eguchi H., Sudo T., Suzuki A., Maehara Y., et al. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells. Annals of Surgical Oncology 2014, 21:3680-3690.
49. Szczubiał M., Łopuszynski W. Prognostic value of regional lymph node status in canine mammary carcinomas. Veterinary and Comparative Oncology 2011, 9:296-303.
50. Tomiyasu H., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. Journal of Veterinary Medical Science 2010, 72:1165-1172.
51. Tomiyasu H., Watanabe M., Goto-Koshino Y., Fujino Y., Ohno K., Sugano S., Tsujimoto H. Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines. Leukemia and Lymphoma 2013, 54:1309-1315.
52. Verdin E. The many faces of sirtuins: Coupling of NAD metabolism, sirtuins and lifespan. Nature Medicine 2014, 20:25-27.
53. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
54. Withrow S.J., Vail D.M., Page R. Withrow and MacEwen's Small Animal Clinical Oncology 2012, 538-556. Saunders Elsevier, St. Louis, MO, USA. Fifth Ed.
55. Xiong N., Long X., Xiong J., Jia M., Chen C., Huang J., Ghoorah D., Kong X., Lin Z., Wang T. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Critical Reviews in Toxicology 2012, 42:613-632.
56. Yeh C.-T., Su C.-L., Huang C.-Y.F., Lin J.K.-Y., Lee W.-H., Chang P.M.-H., Kuo Y.-L., Liu Y.-W., Wang L.-S., Wu C.-H., et al. A preclinical evaluation of antimycin A as a potential antilung cancer stem cell agent. Evidence-Based Complementary and Alternative Medicine 2013, 2013:e910451.
57. Yoshida K., Yoshida S., Choisunirachon N., Saito T., Matsumoto K., Saeki K., Mochizuki M., Nishimura R., Sasaki N., Nakagawa T. The relationship between clinicopathological features and expression of epithelial and mesenchymal markers in spontaneous canine mammary gland tumors. Journal of Veterinary Medical Science 2014, 76:1321-1327.